

Kara L Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5832854/publications.pdf>

Version: 2024-02-01

57
papers

10,055
citations

304602

22
h-index

206029

48
g-index

58
all docs

58
docs citations

58
times ranked

16620
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the hematopoietic factory during acute lymphoblastic leukemia. <i>Pediatric Research</i> , 2022, 91, 1023-1024.	1.1	2
2	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	13.7	339
3	An instructive role for Interleukin-7 receptor β in the development of human B-cell precursor leukemia. <i>Nature Communications</i> , 2022, 13, 659.	5.8	12
4	CytofIn enables integrated analysis of public mass cytometry datasets using generalized anchors. <i>Nature Communications</i> , 2022, 13, 934.	5.8	8
5	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 781-794.	1.8	10
6	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR ⁺ refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	0.6	51
7	Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. <i>Laryngoscope</i> , 2021, 131, E1941-E1949.	1.1	24
8	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, i49-i50.	0.6	6
9	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
10	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
11	Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 881-896.	1.0	3
12	Use of cardiac radiation therapy as bridging therapy to CAR ⁺ for relapsed pediatric B ⁺ cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28870.	0.8	8
13	Mass Cytometry of Hematopoietic Cells. <i>Methods in Molecular Biology</i> , 2021, 2185, 65-76.	0.4	3
14	Inhibition of Pre-BCR Signaling Mediates a Metabolic Switch in B-Cell Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 615-615.	0.6	0
15	Gene Expression Analysis of CML Patients across the Age Spectrum. <i>Blood</i> , 2021, 138, 1473-1473.	0.6	0
16	Glucocorticoid-Resistant B-Cell Acute Lymphoblastic Leukemic Cells Can be Targeted By BCR-Signaling Inhibition. <i>Blood</i> , 2021, 138, 617-617.	0.6	0
17	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	0.6	4
18	Chromatin Content Capture Reveals Acute Leukaemia Oncogenic Vulnerability Point in Human B Cell Development. <i>Blood</i> , 2021, 138, 673-673.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. <i>Cancers</i> , 2021, 13, 6263.	1.7	7
20	Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions. <i>Nature Machine Intelligence</i> , 2020, 2, 619-628.	8.3	52
21	Progressive B Cell Loss in Revertant X-SCID. <i>Journal of Clinical Immunology</i> , 2020, 40, 1001-1009.	2.0	5
22	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 541-550.	5.1	202
23	A Cancer Biologist's Primer on Machine Learning Applications in High“Dimensional Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 782-799.	1.1	17
24	Supercharging your CAR. <i>Blood</i> , 2020, 135, 593-594.	0.6	2
25	Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2020, 22, 11.	1.8	13
26	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. <i>Oncotarget</i> , 2020, 11, 2387-2403.	0.8	18
27	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
28	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1710-1718.	5.1	65
29	Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2019, 79, 2339-2351.	0.4	55
30	A novel platform for isotype-specific testing of autoantibodies. <i>PLoS ONE</i> , 2019, 14, e0211596.	1.1	1
31	High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells. <i>Blood Advances</i> , 2019, 3, 2825-2835.	2.5	34
32	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	0.6	42
33	Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction. <i>Blood</i> , 2019, 134, 4471-4471.	0.6	0
34	Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. <i>Nature Medicine</i> , 2018, 24, 474-483.	15.2	112
35	DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4294-E4303.	3.3	42
36	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	13.9	3,680

#	ARTICLE	IF	CITATIONS
37	Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry. <i>Journal of Immunology</i> , 2018, 200, 336-346.	0.4	89
38	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3192-3202.	0.8	110
39	Single-cell mass cytometry and machine learning predict relapse in childhood leukemia. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1472057.	0.3	3
40	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. <i>Blood</i> , 2018, 131, 2596-2598.	0.6	18
41	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 895-895.	0.6	70
42	Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells. <i>Blood</i> , 2018, 132, 4246-4246.	0.6	5
43	Nicosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. <i>Oncotarget</i> , 2018, 9, 4301-4317.	0.8	22
44	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 22872-22885.	0.8	11
45	High-resolution myogenic lineage mapping by single-cell mass cytometry. <i>Nature Cell Biology</i> , 2017, 19, 558-567.	4.6	108
46	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.3	23
47	Automated mapping of phenotype space with single-cell data. <i>Nature Methods</i> , 2016, 13, 493-496.	9.0	344
48	BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 280-280.	0.6	5
49	Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. <i>Cell</i> , 2015, 162, 184-197.	13.5	1,791
50	Single-Cell Trajectory Detection Uncovers Progression and Regulatory Coordination in Human B Cell Development. <i>Cell</i> , 2014, 157, 714-725.	13.5	838
51	The Split Virus Influenza Vaccine rapidly activates immune cells through Fc γ 3 receptors. <i>Vaccine</i> , 2014, 32, 5989-5997.	1.7	34
52	viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. <i>Nature Biotechnology</i> , 2013, 31, 545-552.	9.4	1,481
53	Single Cell Trajectory Detection Orders Hallmarks of Early Human B Cell Development. <i>Blood</i> , 2012, 120, 1044-1044.	0.6	3
54	Dimensionality Reduction Reveals Distinct Shapes of Normal and Malignant Hematopoietic Cell Populations. <i>Blood</i> , 2012, 120, 1451-1451.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Mass Cytometry Organizes the Heterogeneity of Pediatric B Cell Acute Lymphoblastic Leukemia. Blood, 2011, 118, 753-753.	0.6	0
56	Signaling and Immunophenotypic Diversity in Pediatric Acute Myeloid Leukemia As Defined by 31-Parameter Single-Cell Mass Cytometry. Blood, 2011, 118, 2565-2565.	0.6	0
57	2008 WHO Classification of Pediatric AML.. Blood, 2010, 116, 1044-1044.	0.6	0